Hello Dew,
The David Sobek email you posted earlier was a curious read, as the method of operation of Bavituximab against cancer is different (per Dr. Thorpe's papers) than what was described. If you would guide your associate to the IBox on the PPHM Board, CJ has done a nice job with posting references such that those who received misunderstandings about Bavituximab's FDA approval of a NSCLC Phase 3 trial design can learn for themselves. The University of Texas South West material on Dr. Thorp's research and the PPHM company web page are also resource areas. The three ASCO Poster presentations (around June 1) may also be helpful if there are parties on the BV board interested in the Bavi trial science. Mr Sobek may not know he is not correctly describing the role of Bavi in cancer trials, considering the mechanisms described through the inventor's research.
I was pleasantly surprised to see the convergence of trial reporting events was able to be highlighted by the FDA Phase 3 trial design approval of Bavi just before ASCO and the Russell rebalancing cutoff. In addition to investor interest in the Bavi trials, short interest is running just under 10% of outstanding PPHM shares and Russell rebalancing might add about 8% of shares additional buying pressure, due to be reconciled over a brief five or six week period. If it turns out that PPHM does have a partner soon to reveal their presence offering favorable terms to PPHM, I wonder how that demand for about 20 million shares to cover short interest and Russell rebalancing will impact the pps? The Phase 3 FDA approval, ASCO interest, and prospective partner announcement may all gets intertwined. We shall see.
Best wishes and IMO.
KT
AI
Market Data 
Markets 
